Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04714983
Other study ID # 2440LM-002
Secondary ID
Status Suspended
Phase Phase 1
First received
Last updated
Start date February 15, 2021
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source DNAtrix, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.


Recruitment information / eligibility

Status Suspended
Enrollment 30
Est. completion date December 31, 2026
Est. primary completion date July 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Male or female aged = 18 years at time of consent - Diagnosis of liver metastases from colorectal, breast, gastric, periampullary, melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal stromal tumor - Multiple (= 2) liver tumors - Candidate for curative-intent surgery - Stated willingness to comply with all study procedures and availability for the duration of the study. - Candidates eligible for targeted therapy, as per standard of care guidelines (and based on mutational status as indicated), must have completed therapy - Preoperative chemotherapy is allowed Key Exclusion Criteria: - Recurrence of liver metastasis - Diagnosis of neuroendocrine tumor liver metastasis - Liver metastasis treated with > 12 cycles of systemic chemotherapy - Condition that requires ongoing systemic immunosuppressive therapy - Evidence of inadequate organ function based on lab parameters - Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) or total bilirubin > 5x the upper limits of normal - Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with DNX-2440

Study Design


Intervention

Biological:
DNX-2440
DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.

Locations

Country Name City State
United States H. Lee Moffitt Cancer Center and Research Institute, Inc. Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
DNAtrix, Inc. H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) achieved during dose-escalation phase The MTD will be defined as the highest tolerated dose below the dose that results in greater than or equal to one-third of the subjects exposed who experience a dose-limiting toxicity (DLT). 1.5 Years
Secondary Efficacy of DNX-2440 assessed by Tumor Regression Grade (TRG) score Efficacy in tumor cell killing will be measured using the TRG score (1-5) for the resected specimens 3 Years
Secondary Viral replication Viral replication will be assessed by quantitative measurement of viral protein expression by IHC 3 Years
Secondary Measure Immune response with cell response panels Immunotherapeutic responses will be assessed by examining features and measuring changes following the intervention for Immunologic microenvironment (T-cell and Myeloid-cell response panels-tissue). 3 Years
Secondary Measure Immune response with ImmunoSEQsec Immunotherapeutic responses will be assessed by measuring changes in T-cell receptor (TCR) repertoire - tissue and blood. 3 Years
Secondary Measure Immune response with ELISPOT Immunotherapeutic responses will be assessed by measuring T-cell response (ELISPOT - tissue/blood). 3 Years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A